Table 1. Demographic and clinical characteristics of the adult participants.
| n | Mean (s.d.) | Median | Range | P | |
|---|---|---|---|---|---|
| Age | |||||
| ADHD (m/f) | 8/8 | 38.4 (11.8) | 37.6 | 23.7–61.1 | 0.04a |
| Control (m/f) | 19/19 | 31.6 (9.2) | 27.5 | 21.0–50.6 | |
| WURS-k Sum | |||||
| ADHD | 16 | 33.4 (11.1) | 34 | 13.0–51.0 | <0.001a |
| Control | 30 | 12.9 (10.4) | 10 | 0.0–38.0 | |
| CAARS-S:L (ADHD-Index) | |||||
| ADHD | 16 | 63.0 (8.4) | 62 | 51.0–79.0 | <0.001a |
| Control | 30 | 44.9 (5.7) | 43 | 36.0–62.0 | |
| CAARS-O:L (ADHD-Index) | |||||
| ADHD | 13 | 64.6 (11.8) | 63 | 49.0–83.0 | <0.001b |
| Control | 28 | 46.6 (6.1) | 48 | 37.0–58.0 | |
| Medication | |||||
| ADHD | Methylphenidate (n=14); trazodone (n=2)c; dexmethylphenidate (n=2); bupropion (n=1); agomelatine (n=1); amitriptyline (n=1)c; prednisone (n=1); oral contraceptives (n=3) | ||||
| Control | Finasteride (n=1); fluorouracil (n=1)d; salicylic acid (n=1); paracetamol (n=1); minoxidil (n=1); oral contraceptives (n=8) | ||||
| Comorbidities | |||||
| ADHD | Sleep problems (n=1) | ||||
| Control | None | ||||
| Handedness | |||||
| ADHD (r/l) | 13/3 | ||||
| Control (r/l) | 32/6 | ||||
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CAARS, Conners' Adult ADHD Rating Scales; f, female; l, left-handed; m, male; n, number of participants; r, right-handed; WURS, Wender Utah Rating Scale.
a
Two-tailed Wilcoxon rank-sum test.
b
Two-tailed two-sample t-test.
c
Current or previous reported use for sleep problems.
d
Prescribed for skin warts.